← Back to Screener
Citius Pharmaceuticals Inc. Common (CTXR)
Price$0.56
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-69.04%
Price vs S&P 500 (4W)-12.49%
VGM Score18.46
Market Capitalization$15.43M
All Metrics
Book Value / Share (Quarterly)$2.75
P/TBV (Annual)3.37x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.89
Price vs S&P 500 (YTD)-36.09%
EPS (TTM)$-2.59
10-Day Avg Trading Volume0.47M
EPS Excl Extra (TTM)$-2.59
EPS (Annual)$-3.38
ROI (Annual)-54.61%
Cash / Share (Quarterly)$0.21
ROA (Last FY)-28.59%
EBITD / Share (TTM)$-2.90
ROE (5Y Avg)-39.45%
Cash Flow / Share (Annual)$-1.79
P/B Ratio0.25x
P/B Ratio (Quarterly)0.33x
Net Income / Employee (Annual)$-1,627,600
Net Interest Coverage (TTM)-244.30x
ROA (TTM)-34.75%
EPS Incl Extra (Annual)$-3.38
Current Ratio (Annual)0.62x
Quick Ratio (Quarterly)0.10x
3-Month Avg Trading Volume0.72M
52-Week Price Return-34.58%
Revenue / Employee (TTM)$244,000
Tangible BV / Share (Quarterly)$3.73
52-Week High$2.48
EPS Excl Extra (Annual)$-3.38
Tangible BV CAGR (5Y)29.89%
26-Week Price Return-61.11%
Quick Ratio (Annual)0.09x
13-Week Price Return-40.99%
Total Debt / Equity (Annual)0.01x
Current Ratio (Quarterly)0.58x
Enterprise Value$10.84M
Book Value / Share Growth (5Y)43.89%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.24
3-Month Return Std Dev130.08%
Net Income / Employee (TTM)$-2,008,700
ROE (Last FY)-55.42%
Net Interest Coverage (Annual)-86.29x
EPS Basic Excl Extra (Annual)$-3.38
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.59
ROI (TTM)-66.70%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$4.95
Forward P/E0.28x
Price vs S&P 500 (52W)-58.95%
Year-to-Date Return-27.93%
5-Day Price Return-11.67%
EPS Normalized (Annual)$-3.38
ROA (5Y Avg)-27.85%
Month-to-Date Return-14.49%
Cash Flow / Share (TTM)$-0.21
EBITD / Share (Annual)$-3.48
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-39.29%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-2.59
P/TBV (Quarterly)3.64x
P/B Ratio (Annual)0.33x
Book Value / Share (Annual)$3.74
Price vs S&P 500 (13W)-49.25%
Beta1.03x
Revenue / Share (TTM)$0.25
ROE (TTM)-67.43%
52-Week Low$0.48
mGradeF
vgmGradeF
Show chart for
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CTXRCitius Pharmaceuticals Inc. Common | — | — | F | $0.56 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Citius Pharmaceuticals develops first-in-class targeted oncology therapies, with LYMPHIR—an engineered IL-2 diphtheria toxin fusion protein—as its flagship product candidate. The company addresses unmet medical needs in oncology and adjunct cancer care with a lower development risk profile than typical new chemical entities.